{
    "clinical_study": {
        "@rank": "10002", 
        "arm_group": {
            "arm_group_label": "one arm", 
            "arm_group_type": "Experimental", 
            "description": "Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day."
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the efficacy of icotinib at routine dose in previously\n      treated non/light-smoking patients with advanced squamous cell lung cancer."
        }, 
        "brief_title": "Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma of Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to evaluate the efficacy of icotinib at routine dose in previously\n      treated non/light-smoking patients with advanced squamous cell lung cancer. An objective\n      response (OR) was defined as a patient having a best overall response of either complete\n      response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid\n      Tumors, confirmed at least 28 days following the date of the initial response."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed metastatic or recurrent squamous cell lung\n             cancer from the primary lesion and/or lymph nodes, stage IIIB or IV patients with\n             non-smoking or light-smoking history.\n\n          -  Failure of at least 1, and no more than 2, prior chemotherapy regimens for advanced\n             disease (either due to progressive disease or toxicity).\n\n          -  Have measurable disease, defined as at least one lesion that can be accurately\n             measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with\n             conventional techniques or as >= 10 mm with spiral CT scan.\n\n          -  Be >= 18 years of age.\n\n          -  Expected survival period over 12 weeks;\n\n          -  ECOG PS 0-2. Adequate organ system function as defined within the protocol.\n\n          -  Patients with a history of CNS metastases or cord compression are allowed if they\n             have been definitively treated and are clinically stable.\n\n          -  Consent compliance research plan and follow-up process, and be able to carry out oral\n             therapy; Provision of written informed consent.\n\n          -  In women of childbearing age, must be in before starting treatment within 7 day of\n             urine pregnancy test and the result is negative, and not in the lactation period, and\n             reproductive age men and women prior to entry into the study, the research process\n             until 90 days after stopping all agree to use reliable methods of contraception;\n\n          -  Weight loss =< 10% in past 6 months.\n\n          -  Adequate tumor tissue for detection of molecular biomarkers.\n\n        Exclusion Criteria:\n\n          -  Patients who have previously received treatment with EGFR-TKIs.\n\n          -  Concomitant treatment with any other experimental drug under investigation or\n             anti-tumor therapy;\n\n          -  Symptomatic CNS metastases or newly diagnosed CNS metastases that have not yet been\n             definitively treated with radiation and/or surgery.\n\n          -  Known severe hypersensitivity to icotinib or any of the excipients of this product.\n\n          -  Presence of uncontrolled pleural effusion or/and peritoneal effusion;\n\n          -  Evidence of any other significant clinical disorder or laboratory finding that makes\n             it undesirable for the subject to participate in the study.\n\n          -  Past or current history of neoplasm (other than the entry diagnosis) in past 5 years,\n             with the exception of treated basal cell carcinoma or carcinoma in situ of the\n             cervix, or other cancers cured by local therapy alone.\n\n          -  Women who are lactating.or have positive pregnancy test."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009605", 
            "org_study_id": "ZYTOP 1401"
        }, 
        "intervention": {
            "arm_group_label": "one arm", 
            "description": "125mg, oral administration, three times per day.", 
            "intervention_name": "Icotinib", 
            "intervention_type": "Drug", 
            "other_name": "BPI-2009"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "icotinib, SCC", 
        "lastchanged_date": "December 8, 2013", 
        "location": {
            "contact": {
                "last_name": "Zhao Qiong, Dr."
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310003"
                }, 
                "name": "79 Qingchun Road"
            }, 
            "investigator": {
                "last_name": "Zhao Qiong, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer", 
        "other_outcome": {
            "measure": "Life quality", 
            "safety_issue": "Yes", 
            "time_frame": "14 months"
        }, 
        "overall_contact": {
            "email": "tango654321@gmail.com", 
            "last_name": "Wang Yi Na, Dr."
        }, 
        "overall_official": {
            "affiliation": "Zhejiang University", 
            "last_name": "Zhao Qiong, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, confirmed at least 28 days following the date of the initial response.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "4 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009605"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Prof.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression free survival was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Overall Survival was assessed via calculation of the time to death due to any cause. If a participant was known to have died, the time to death was defined as the time from the date of randomization to the date of death. Otherwise, a participant was censored at the last date they were known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "14 months"
            }, 
            {
                "description": "Adverse events, serious adverse events, incidence of and reason for study drug dose interruptions and discontinuations, laboratory assessments, vital signs.", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}